Description

pharmachologic effect

Ksizal is an anti-allergic agent.

The active substance of the drug is levocetirizine, the enantiomer of cetirizine, belongs to the group of competitive histamine antagonists.

Levocetirizine affects the histamine-dependent stage of allergic reactions, and also reduces the migration of eosinophils, reduces vascular permeability, and limits the release of inflammatory mediators.

It prevents the development and facilitates the course of allergic reactions, has an anti-exudative, antipruritic effect, practically does not have an anticholinergic and antiserotonin effect.

In therapeutic doses, it practically does not have a sedative effect.

Indications

For adults and children over 6 years of age: treatment of symptoms of perennial and seasonal allergic rhinitis and allergic conjunctivitis, such as itching, sneezing, lacrimation, conjunctival hyperemia

hay fever (hay fever)

urticaria, including chronic idiopathic urticaria, Quincke's edema

other allergic dermatoses, accompanied by itching and rashes.

Contraindications

Hypersensitivity to any component of the drug or piperazine derivatives.

Severe chronic renal failure (creatinine clearance less than 10 ml / min).

Children's age (up to 6 years old).

With caution - chronic renal failure (correction of the dosage regimen is required), old age (a decrease in glomerular filtration is possible).

special instructions

An objective assessment of the ability to drive a car and work with mechanisms did not reliably reveal any undesirable effects when the recommended dose of 5 mg was prescribed, however, it is advisable to refrain from engaging in potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

Structure

1 tablet contains 5 mg levocetirizine dihydrochloride.

Method of administration and dosage

It is taken orally with food or on an empty stomach, with a small amount of water without chewing.

Adults and children over 6 years old: daily dose - 5 mg (1 tablet).

Elderly patients (subject to normal renal function) dose reduction is not required.

For patients with chronic renal failure, the dose is reduced by half (1 tablet every other day) with CC from 30 to 49 ml / min and 3 times (1 tablet every 3 days) with CC from 10 to 29 ml / min.

Patients with hepatic insufficiency do not need to correct the dosage regimen.

The duration of admission depends on the disease.

For the treatment of pollinosis, it is prescribed on average for 1-6 weeks.

In chronic diseases (perennial rhinitis, atonic dermatitis), the duration of treatment may increase to 18 months.

Side effects

Headache, drowsiness, dry mouth, fatigue.

Rarely - migraine, dizziness, dyspeptic disorders, allergic reactions (angioedema, rash, urticaria, itching).

Drug interactions

Concomitant use with macrolides or ketoconazole did not cause significant changes in the ECG.

Co-administration with theophylline (400 mg / day) reduces the total clearance of levocetirizine by 16% (the theophylline kinetics does not change).

When used in therapeutic doses, no data have been obtained on interaction with alcohol.

However, you should refrain from drinking alcoholic beverages.

Overdose

Symptoms: may be accompanied by signs of intoxication in the form of drowsiness in children, an overdose of the drug may be accompanied by anxiety and increased irritability.

Treatment: if symptoms of an overdose appear (especially in children), the drug should be discontinued, gastric lavage, activated charcoal intake, symptomatic therapy are necessary.

There is no specific antidote.

Storage conditions

In a dry place, at a temperature not exceeding 25 ° C.

Shelf life 4 years

Active substance

Levocetirizine

Name ENG

XYZAL

Clinical and pharmacological group

Blocker of histamine H1 receptors.

Antiallergic drug

ATX code

Levocetirizine

Dosage

5mg

Structure

1 tablet contains 5 mg levocetirizine dihydrochloride.

Indications

For adults and children over 6 years of age: treatment of symptoms of perennial and seasonal allergic rhinitis and allergic conjunctivitis, such as itching, sneezing, lacrimation, conjunctival hyperemia

hay fever (hay fever)

urticaria, including chronic idiopathic urticaria, Quincke's edema

other allergic dermatoses, accompanied by itching and rashes.

INN / Active ingredient

Levocetirizine

Storage conditions and periods

In a dry place, at a temperature not exceeding 25 degrees.

Expiration date: 4 years

Specifications